Update: Mallinckrodt provides additional information on Dutch High-Flux Reactor

January 10, 2013


On January 9, 2013, Mallinckrodt, the Pharmaceutical business of Covidien, provided additional information regarding the operational status of the Dutch High-Flux Reactor.  The NRG expects to provide another update by January 17, and at least two weeks’ notice prior to the restart date.

For more information, please click on the attached letter. 

Mallinckrodt Letter